靶向CD70的透明细胞肾细胞癌免疫PET/CT显像:一项转化研究
研究检测肾细胞癌中CD70表达,制备两种靶向CD70的单域抗体RCCB3和RCCB6并用68Ga标记,在患者来源异种移植模型中行免疫PET/CT,并在8例肾细胞癌患者中开展初步临床试验评估诊断效用;结果显示[68Ga]Ga-NOTA-RCCB6在特异性识别CD70阳性转移灶方面优于传统18F-FDG PET/CT。
要点
- CD70在透明细胞肾细胞癌中高表达且与性别、肿瘤分化、瘤栓、坏死、远处转移及总生存相关。
- 两种新型CD70单域抗体RCCB3和RCCB6对重组人CD70具有高亲和力,68Ga标记后行免疫PET/CT可清晰快速显示皮下透明细胞肾细胞癌。
- 在8例肾细胞癌患者的初步临床试验中,[68Ga]Ga-NOTA-RCCB6 PET/CT在特异性识别CD70阳性透明细胞肾细胞癌转移灶方面优于传统18F-FDG PET/CT。
核心结论
- 采用[68Ga]Ga-NOTA-RCCB6或[68Ga]Ga-NOTA-RCCB3的CD70靶向免疫PET/CT显像是评估透明细胞肾细胞癌患者肿瘤负荷和可疑转移的精准且更优的方法。
- 该显像技术的进步有潜力显著改善该患者群体的临床决策过程。
研究设计与样本
- 转化研究:采用免疫组织化学染色检测并分析多种肾细胞癌和正常肾脏中CD70表达。
- 制备两种新型CD70特异性单域抗体RCCB3和RCCB6,并用68Ga标记开发放射性示踪剂。
- 在皮下透明细胞肾细胞癌患者来源异种移植模型中行[68Ga]Ga-NOTA-RCCB3和[68Ga]Ga-NOTA-RCCB6免疫PET/CT显像。
- 招募8例肾细胞癌患者开展初步临床试验(ClinicalTrials.gov标识:NCT06148220),评估[68Ga]Ga-NOTA-RCCB3和[68Ga]Ga-NOTA-RCCB6免疫PET/CT的诊断效用。
主要发现
- CD70表达与肾细胞癌患者的性别、肿瘤分化、瘤栓、坏死、远处转移及总生存相关。
- RCCB3和RCCB6对重组人CD70具有高亲和力。
- [68Ga]Ga-NOTA-RCCB3和[68Ga]Ga-NOTA-RCCB6免疫PET/CT显像可清晰快速显示皮下透明细胞肾细胞癌。
- 阻断CD70后,[68Ga]Ga-NOTA-RCCB6的肿瘤摄取显著降低。
- 在透明细胞肾细胞癌患者中,[68Ga]Ga-NOTA-RCCB6 PET/CT在特异性识别CD70阳性透明细胞肾细胞癌转移方面优于传统18F-FDG PET/CT。
关键数值与推荐
- 8例肾细胞癌患者纳入初步临床试验(NCT06148220),评估[68Ga]Ga-NOTA-RCCB3和[68Ga]Ga-NOTA-RCCB6免疫PET/CT的诊断效用。
- [68Ga]Ga-NOTA-RCCB6 PET/CT在透明细胞肾细胞癌患者中特异性识别CD70阳性转移灶方面优于传统18F-FDG PET/CT。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The diagnosis and surveillance of clear cell renal cell carcinoma (ccRCC) remains a clinical challenge. The high and specific expression of the cluster of differentiation 70 (CD70) in ccRCC makes it a potential diagnostic and therapeutic target. Methods: We detected and analyzed CD70 expression in various renal cell carcinomas (RCCs) and normal kidneys using immunohistochemical staining. Two novel CD70-specific single-domain antibodies, RCCB3 and RCCB6, were produced and labeled with 68Ga to develop radiotracers. We performed immuno-PET/CT imaging with [68Ga]Ga-NOTA-RCCB3 and [68Ga]Ga-NOTA-RCCB6 in subcutaneous ccRCC patient-derived xenograft models. We recruited 8 RCC patients in a pilot clinical trial (ClinicalTrials.gov identifier: NCT06148220) to evaluate the diagnostic utility of [68Ga]Ga-NOTA-RCCB3 and [68Ga]Ga-NOTA-RCCB6 immuno-PET/CT. Results: Expression of CD70 is associated with sex, tumor differentiation, tumor thrombus, necrosis, distant metastasis, and overall survival of RCC patients. RCCB3 and RCCB6 had high affinities for recombinant human CD70. Immuno-PET/CT imaging with [68Ga]Ga-NOTA-RCCB3 and [68Ga]Ga-NOTA-RCCB6 rapidly visualized subcutaneous ccRCC with clarity. Tumor uptake of [68Ga]Ga-NOTA-RCCB6 was significantly reduced after the blockade of CD70. [68Ga]Ga-NOTA-RCCB6 PET/CT in ccRCC patients outperformed traditional 18F-FDG PET/CT in specifically identifying CD70-positive ccRCC metastases. Conclusion: CD70-targeted immuno-PET/CT imaging with [68Ga]Ga-NOTA-RCCB6 or [68Ga]Ga-NOTA-RCCB3 is a precise and superior method for evaluating tumor burden and suspected metastases in ccRCC patients. This advancement in imaging technology has the potential to improve the clinical decision-making process for this patient cohort significantly.
引用
- Zhou X, Wu Q, Zhai W, et al. CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study. J Nucl Med. 2024. PMID: 39510586. doi:10.2967/jnumed.124.268509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。